News

Filter

Current filters:

ResearchAbbVie

1 to 9 of 37 results

ASH 2014: AbbVie's venetoclax shows promise in Phase II trial

ASH 2014: AbbVie's venetoclax shows promise in Phase II trial

08-12-2014

US drugmaker AbbVie presented data at the American Society of Hematology’s annual meeting, demonstrating…

AbbVieOncologyPharmaceuticalResearchUSA

AbbVie signs agreement with Medicines Patent Pool for lopinavir and retonavir in pediatric HIV

AbbVie signs agreement with Medicines Patent Pool for lopinavir and retonavir in pediatric HIV

01-12-2014

US drugmaker AbbVie and the Medicines Patent Pool have agreed a licensing agreement for lopinavir and…

AbbVieAnti-viralsLopinavirPharmaceuticalResearchRitonavir TabletsUSA

EMA responds to Ombudsman questioning of AbbVie trial redactions

13-11-2014

The European Medicines Agency says it has taken note of the European Ombudsman’s recent remarks on…

AbbVieAnti-Arthritics/RheumaticsEuropeHumiraPharmaceuticalRegulationResearch

New data show strong cure rates with AbbVie’s hep C therapy in HIV and transplant patient studies

New data show strong cure rates with AbbVie’s hep C therapy in HIV and transplant patient studies

11-11-2014

US pharma company AbbVie got a boost for its upcoming hepatitis C treatment regimen, with the company…

AbbVieAnti-viralsPharmaceuticalResearchUSA

Gastroenterologists underestimate Crohn’s disease and UC in patients

Gastroenterologists underestimate Crohn’s disease and UC in patients

27-10-2014

Most physicians underestimate the severity of moderate or severe inflammatory bowel disease, specifically…

AbbVieGastro-intestinalsPharmaceuticalResearchUSA

New Ph III data to support filing for AbbVie’s Humira in HS

13-10-2014

US pharma company AbbVie has reported new data with its mega blockbuster arthritis drug Humira (adalimumab)…

AbbVieAnti-Arthritics/RheumaticsDermatologicalsHumiraPharmaceuticalResearch

Ph III study of Amgen’s Humira biosimilar ABP 501 meets endpoint in psoriasis

Ph III study of Amgen’s Humira biosimilar ABP 501 meets endpoint in psoriasis

09-10-2014

US biotech major Amgen says its Phase III study evaluating the efficacy and safety of its biosimilar…

AbbVieABP 501AmgenAnti-Arthritics/RheumaticsBiosimilarsBiotechnologyDermatologicalsHumiraResearchUSA

Biogen and AbbVie report reduced disease activity with MS drug Zinbryta

Biogen and AbbVie report reduced disease activity with MS drug Zinbryta

18-09-2014

US biotech company Biogen Idec and US pharma giant AbbVie have announced the full results from the Phase…

AbbVieAvonexBiogen IdecImmune systemMultiple sclerosisNeurologicalPharmaceuticalResearchUSAZinbryta

1 to 9 of 37 results

COMPANY SPOTLIGHT

Menarini

Back to top